Analyst Price Targets — MNKD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 10:14 am | — | Wells Fargo | $13.00 | $4.10 | TheFly | MannKind price target lowered to $13 from $14 at Wells Fargo |
| July 30, 2026 10:28 am | — | Wells Fargo | $14.00 | $3.98 | TheFly | MannKind price target raised to $14 from $11 at Wells Fargo |
| June 1, 2026 1:08 am | — | Wells Fargo | $11.00 | $3.77 | TheFly | MannKind price target raised to $11 from $10 at Wells Fargo |
| May 7, 2026 11:15 am | Anthony Petrone | Mizuho Securities | $7.00 | $3.56 | TheFly | MannKind price target lowered to $7 from $8 at Mizuho |
| May 7, 2026 10:39 am | — | Wells Fargo | $10.00 | $3.56 | TheFly | MannKind price target raised to $10 from $8 at Wells Fargo |
| May 7, 2026 10:02 am | — | H.C. Wainwright | $10.00 | $3.56 | TheFly | MannKind price target raised to $10 from $8 at H.C. Wainwright |
| April 13, 2026 2:44 pm | — | Mizuho Securities | $8.00 | $2.58 | TheFly | MannKind price target lowered to $8 from $10 at Mizuho |
| April 8, 2026 12:27 pm | — | Truist Financial | $6.00 | $2.61 | TheFly | MannKind price target lowered to $6 from $7 at Truist |
| November 24, 2025 12:24 pm | — | Truist Financial | $9.00 | $5.03 | TheFly | MannKind initiated with a Buy at Truist |
| September 2, 2025 1:42 pm | — | H.C. Wainwright | $11.00 | $5.74 | TheFly | MannKind price target raised to $11 from $9 at H.C. Wainwright |
Latest News for MNKD
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNKD.
U.S. House Trading
No House trades found for MNKD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.